2. Academic Validation
  3. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity

Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity

  • Bioorg Med Chem. 2020 Mar 15;28(6):115345. doi: 10.1016/j.bmc.2020.115345.
Bocheng Wu 1,  Shaghayegh Fathi 1,  Shanee Mortley 1,  Mahir Mohiuddin 2,  Young C Jang 3,  Adegboyega K Oyelere 4
Affiliations

Affiliations

  • 1 School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332-0400 USA.
  • 2 Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332-0400 USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30332-0400 USA.
  • 3 School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30332-0400 USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30332-0400 USA.
  • 4 School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332-0400 USA; Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332-0400 USA. Electronic address: [email protected].
PMID: 32061484 DOI: 10.1016/j.bmc.2020.115345
Abstract

Signal transducer and activator of transcription 3 (STAT3) is an oncogenic transcription factor which has been recognized as a promising Cancer therapeutic target. Small molecule pyrimethamine (PYM) is a known direct inhibitor of activated STAT3 and it is currently under clinical trial. Also, histone deacetylase (HDAC) inhibition has been shown to indirectly attenuate STAT3 signaling through inhibition of STAT3 activation. Herein we described the design and biological profiling of two classes of PYM-conjugated HDAC inhibitors (HDACi). We observed that the class I PYM-HDACi compounds 12a-c potently inhibited HDACs 1 and 6 in cell free assays while a lead class II PYM-HDACi compound 23 showed a strong HDAC 6 selective inhibition. In a cell-based assay, 12a-c are preferentially cytotoxic to MDA-MB-231, a TNBC cell line that is highly STAT3-dependent, while 23 showed no such selective toxicity. Subsequent target validation studies revealed that a representative class I PYM-HDACi compound 12c elicited a signature of HDAC and STAT3 pathway inhibition intracellularly. Collectively, these data suggest that PYM-HDACi compounds are promising leads to develop targeted therapy for TNBC.

Keywords

HDAC inhibitor; Histone deacetylase inhibitors; Histone deacetylases; Molecular docking; Pyrimethamine; STAT proteins; STAT3; STAT3 pathway; Triple Negative Breast Cancer.

Figures
Products